Search Result

Results for "

HER2 breast cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Cytotoxin (1) Akt (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (7) Apoptosis (8) Bacterial (1) Btk (1) CDK (11) Dihydrofolate reductase (DHFR) (2) Drug Derivative (1) Drug-Linker Conjugates for ADC (2) EGFR (27) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (5) Fatty Acid Synthase (FASN) (2) HSP (4) Isotope-Labeled Compounds (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (1) mTOR (1) PROTACs (2) Radionuclide-Drug Conjugates (RDCs) (2) Ser/Thr Protease (1) Wnt (1)
By Research Areas:	Cancer (63) Infection (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: BCRP BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-164992

Trastuzumab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Trastuzumab MMAE is an anti-human *epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab MMAE is composed of a humanized anti-HER2* antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer .

HY-P9907

Trastuzumab 30+ Cited Publications Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

Trastuzumab (anti-HER2) 30+ Cited Publications Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2* signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P9912A

Pertuzumab (anti-HER2)	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a *HER2*-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-143323

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active *HER2* inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .

HY-151162

HER2-IN-12	EGFR	Cancer
HER2-IN-12 is a *HER2* inhibitor (IC₅₀: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .

HY-151118

HER2-IN-11	Apoptosis	Cancer
HER2-IN-11 is a psoralen derivative. HER2-IN-11 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-11 induces apoptosis .

HY-151116

HER2-IN-10	Apoptosis	Cancer
HER2-IN-10 is a psoralen derivative. HER2-IN-10 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-10 induces apoptosis .

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets *HER2. Nelipepimut-S has immune activity against HER2* positive breast cancer .

HY-50767

Palbociclib Maximum Cited Publications 170 Publications Verification PD 0332991	CDK	Cancer
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767B

Palbociclib dihydrochloride PD-0332991 dihydrochloride	CDK	Cancer
Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767C

Palbociclib hydrochloride Maximum Cited Publications 170 Publications Verification PD-0332991 hydrochloride	CDK	Cancer
Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767A

Palbociclib monohydrochloride Maximum Cited Publications 170 Publications Verification PD 0332991 monohydrochloride	CDK	Cancer
Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-A0065

Palbociclib isethionate Maximum Cited Publications 170 Publications Verification PD 0332991 isethionate	CDK	Cancer
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767D

Palbociclib orotate PD 0332991 orotate	CDK	Cancer
Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a *HER2* signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to *HER2* on cancer cells. This transformation disrupts *HER2* dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on *HER2* positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a *HER2* targeting peptide that binds to *HER2* to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-50767R

Palbociclib (Standard)	CDK	Cancer
Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-151158

EGFR/HER2-IN-7	EGFR	Cancer
EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2-IN-7 is a *EGFR/HER2* kinase and DHFR inhibitor, with IC₅₀s of 0.18 μM (EGFR), 0.146 μM (HER2), respectively. EGFR/HER2-IN-7 shows moderate inhibition on DHFR (IC₅₀=0.907 μM) .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a *HER2*-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer .

HY-138298A

Trastuzumab deruxtecan 1 Publications Verification DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2* antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298

Trastuzumab deruxtecan (solution) 1 Publications Verification DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2* antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-112749

ME-344	Mitochondrial Metabolism	Cancer
ME-344 is a mitochondrial inhibitor. ME-344 has significant biological antitumor activity in HER2-negative **breast cancer** .

HY-136255

Camizestrant 5 Publications Verification AZD-9833	Estrogen Receptor/ERR	Cancer
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER ⁺ HER2-advanced breast cancer .

HY-149633

EGFR/HER2/DHFR-IN-3	EGFR Dihydrofolate reductase (DHFR) Apoptosis	Cancer
EGFR/HER2/DHFR-IN-3 (compound 4c) is a potent dual inhibitor of *EGFR/HER2, with IC₅₀s of 0.138 and 0.092 μM, respectively. EGFR/HER2/DHFR-IN-3 also inhibits DHFR, with an IC₅₀* of 0.193 M. EGFR/HER2/DHFR-IN-3 causes arrest at the S phase of the cell cycle and induces apoptosis in MCF7 breast cancer cells .

HY-151154

EGFR/HER2/DHFR-IN-1	EGFR	Cancer
EGFR/HER2/DHFR-IN-1 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2/DHFR-IN-1 is a multiple inhibitor of *EGFR/HER2* kinase and DHFR, with IC₅₀s of 0.153 μM, 0.108 μM, 0.291 μM, respectively. EGFR/HER2/DHFR-IN-1 arrests cell cycle at G1/S and induces cells apoptosis .

HY-159519

EGFR/HER2-IN-16	Apoptosis EGFR	Cancer
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-149632

EGFR/HER2/DHFR-IN-2	EGFR Dihydrofolate reductase (DHFR)	Cancer
EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor of EGFR, *HER2, and DHFR* (IC₅₀: 0.248, 0.156, 0.138 μM respectively). EGFR/HER2/DHFR-IN-2 has anticancer activities against a panel of cancer cells (IC₅₀: 9.14, 7.33, 14.18, 24.87, 20.07, 6.16 μM for Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7 cells). EGFR/HER2/DHFR-IN-2 reduce breast cancer tumor growth .

HY-112596

H3B-6545 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-112596A

H3B-6545 hydrochloride 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-154790

STn/sialyl-Tn Neu5Aca2-6GalNAc-a-Ser/Thr	Ser/Thr Protease	Cancer
STn/sialyl-Tn is a sialic acid associated with breast cancer and its expression is closely related to HER2-pos. STn/sialyl-Tn can be used as a marker to count cells in malignant nipple discharge (PND) .

HY-157297

CDK-IN-13	CDK	Cancer
CDK-IN-13 (compound 32E) is a potent and selective inhibitor of CDK12/cyclinK with an IC₅₀ of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines .

HY-164489

KU004	EGFR Akt ERK Apoptosis	Cancer
KU004 is a potent dual *EGFR/HER2* inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of *HER2, EGFR* and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a quinazoline derivative .

HY-121250

Fasnall	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC₅₀ of 3.71 μM. Fasnall induces apoptosis in HER2 ⁺ breast cancer cell lines. Fasnall shows potent anti-tumor activities .

HY-124454

JCC76	Drug Derivative	Cancer
JCC76 is the derivative of Nimesulide (HY-B0363). JCC76 inhibits the proliferation of Her2 positive breast cancer cell SKBR-3 with IC₅₀ of 3.43 μM .

HY-131089

MC-VC-PABC-C6-alpha-Amanitin	Drug-Linker Conjugates for ADC	Cancer
MC-VC-PABC-C6-alpha-Amanitin is an antibody agent conjugate consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a monoclonal antibody MC-VC-PABC-C6. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα. MC-VC-PABC-C6-alpha-Amanitin accurately targets HER2 receptors, specifically recognizes HER2-positive tumor cells. It is widely used in breast cancer and gastric cancer research .

HY-110354

UCM05 G28UCM	Fatty Acid Synthase (FASN) Bacterial Antibiotic	Infection Cancer
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.

HY-50767S

Palbociclib-d8 PD 0332991-d₈	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-P9921

Trastuzumab emtansine 2 Publications Verification Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-50767S1

Palbociclib-d4 hydrochloride PD 0332991-d₄ hydrochloride	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-133737

PROTAC BRD4 Degrader-5	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-5 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-5 can potent degrade BRD4 in HER2 positive and negative breast cancer cell lines .

HY-P10686

CH401 peptide	EGFR	Cancer
CH401 peptide is a *HER2*-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .

HY-160694

cBu-Cit-PROTAC BRD4 Degrader-5	PROTACs	Cancer
cBu-Cit-PROTAC BRD4 Degrader-5 is a cBu-Cit conjugated PROTAC degrader. cBu-Cit-PROTAC BRD4 Degrader-5 can potently degrade BRD4 in HER2 positive and negative breast cancer cell lines .

HY-145102

NCT-58	HSP Apoptosis	Cancer
NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

2,306 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,306 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets *HER2. Nelipepimut-S has immune activity against HER2* positive breast cancer .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a *HER2* signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to *HER2* on cancer cells. This transformation disrupts *HER2* dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on *HER2* positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a *HER2* targeting peptide that binds to *HER2* to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P10686

CH401 peptide	EGFR	Cancer
CH401 peptide is a *HER2*-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .

Cat. No.	Product Name	Target	Research Area

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P9907

Trastuzumab Maximum Cited Publications 31 Publications Verification Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

Trastuzumab (anti-HER2) Maximum Cited Publications 31 Publications Verification Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2* signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P9912A

Pertuzumab (anti-HER2)	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

Cat. No.	Product Name	Chemical Structure

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-W654305

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Cat. No.	Product Name		Classification

HY-159519

EGFR/HER2-IN-16		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: